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Chapter 8 
Perchlorate Toxicity and Risk Assessment 
David R.  att tie,' Joan ~ t r a w s o n , ~  and Jay zhao2 
I Air Force Research Laboratoty, WPAFB, OH 45433-5707 
2~oxicology  Excellence for Risk Assessment, Cincinnati, OH 4521 1 
PERCHLORATE OCCURRENCE AND EXPOSURE 
Sources of Perchlorate 
Ammonium perchlorate is the oxidizer ingredient in solid propellant mixtures 
for rockets, missiles and munitions such as Titan, Minuteman, Peacekeeper, 
Hawk, Polaris and the Space Shuttle. Perchlorate salts may also be used in 
medicine, matches, munitions and pyrotechnics (illuminating and signaling 
flares, colored and white smoke generators, tracers, incendiary delays, fuses, 
photo-flash compounds and fireworks). Perchlorate is also found in 
lubricating oils, finished leather, fabric fixer, dyes, electroplating, aluminum 
refining, manufacture of rubber, paint and enamel production, as an additive 
in cattle feed, in magnesium batteries and as a component of automobile air 
bag inflators.' 
Exposure RoutesIPathways 
Perchlorate salts are highly water-soluble and fully ionize in water.2 The 
resulting perchlorate ion is identical whether it is from the ammonium salt or 
another salt such as potassium and its toxicity is due to the perchlorate ion 
(Clod-). Chemicals may enter the human body in several ways, known as 
routes of exposure or pathways. Routes of exposure can include ingestion, 
dermal (skin) absorption and inhalation. The primary route of exposure for 
perchlorate is through ingestion of water from contaminated drinking water 
supplies, although ingestion of contaminated food and milk are other 
potential sources of exposure. 
Absorption through skin and inhalation of perchlorate are minor exposure 
pathways. Compounds most readily absorbed through the skin are primarily 
organic chemicals. Because perchlorate is an inorganic compound and 
Published in PERCHLORATE: ENVIRONMENTAL OCCURRENCE, INTERACTIONS AND TREATMENT, 
ed. Baohua Gu and John D. Coates (Springer, 2006) DOI: 10.1007/0-387-31113-0_8
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completely ionized in water, the potential for dermal absorption of 
perchlorate through intact skin while bathing and washing is unlikely. 
Occupational exposure of workers to perchlorate is primarily through 
inhalation of ammonium perchlorate dust during the commercial production 
or use of perchlorate salts. Occupational exposure in ammonium perchlorate 
production facilities was shown to be higher than potential exposures from 
drinking water or food sources.394 Exposure by inhalation results in 
absorption into the body through the mucous membranes in the respiratory 
and gastrointestinal tracts. Some direct ingestion through the oral route is 
possible, as is dermal contact, but both of these pathways are minor in 
occupational settings. 
PERCHLORATE HEALTH EFFECTS 
Mechanism of Toxicity 
Thyroid hormones are essential to the regulation of oxygen consumption and 
metabolism throughout the body. Thyroid iodine metabolism and the levels 
of thyroid hormone in serum and tissues are regulated by a number of fairly 
well understood homeostatic mechanisms5 Thyrotropin (TSH), a hormone 
synthesized and secreted by the anterior pituitary gland, is the primary 
regulator of thyroidal iodide uptake and other aspects of thyroid f ~ n c t i o n . ~  
The secretion of TSH is regulated by a negative feed-back pathway through 
serum level of T3 and T4. Formation of thyroid hormones is depressed if 
sufficient inhibition of iodide uptake occurs. As a result, increased TSH 
secretion from the anterior pituitary gland will stimulate the thyroid to 
produce more T3 and T4. Inhibition of iodine uptake is the basis for the 
current and former pharmacological uses of perchlorate. 
Perchlorate, like many chemicals and drugs, disrupts one or more steps in the 
synthesis and secretion of thyroid hormones, resulting in subnormal levels of 
T4 and T3 and an associated compensatory increase in secretion of TSH.~ The 
perchlorate ion, because of its similarity to iodide in ionic size and charge, 
competes with iodide for uptake into the thyroid gland by the sodium-iodide 
symporter, a transport mechanism in the membranes of thyroid cells. At high 
doses, this competitive inhibition results in reduced production of the thyroid 
hormones [triiodothyronine (T3) and thyroxin (T4)] and a consequent increase 
in thyroid stimulating hormone (TSH) via a negative feedback loop involving 
the thyroid, pituitary and hypothalamus.8 Subsequent events include 
decreases in serum T4 (and T3), leading to the potential for altered 
neurodevelopment if observed in either mothers or fetuseslneonates, and 
increases in serum TSH, leading to the potential for thyroid hyperplasia and 
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tumors. The repeated observation of thyroid effects such as alterations of 
hormones, increased thyroid weight, and alterations of thyroid 
histopathology (including tumors) from a large number of rat studies on 
perchlorate provide supporting evidence for the proposed mode-of-action, 
and confirms that the perturbation of thyroid hormone economy as the 
primary biological effect of perchlorate. 
Toxicokinetics 
Studies of absorption, distribution, metabolism and elimination (ADME) to 
measure perchlorate kinetics revealed that there was no metabolism of 
perchlorate in either adult rats or humans. Perchlorate is rapidly excreted, 
with urinary half-lives on the order of 4 hours in the rat and 6 hours in 
 human^.^.'^ Kinetics studies were also conducted for fetal and lactational 
time points in rats in parallel with the "Effects" Study. Kinetic studies were 
designed to aid quantitative interspecies extrapolation and form the basis for 
physiologically based pharmacokinetic (PBPK) models for adult rats and 
humans, as well as pregnant and lactating rats. lI,l2,13,l4 The kinetic studies 
were also used to evaluate the mechanism of iodide inhibition by perchlorate 
and the subsequent hormone response. By determining the relative 
sensitivity of rat versus human, the results helped aid interspecies 
extrapolation. The results of PBPK model simulations confirmed that the 
fetus is the most sensitive developmental time point based on extent of iodide 
inhibition. l3 
Animal Toxicity Studies 
In order to determine the health effects of perchlorate in humans, a fairly 
extensive database of animal toxicity studies was developed in keeping with 
risk assessment guidelines and the mechanism of action of perchlorate. 
Several studies of perchlorate in rodents have been conducted in which 
hormone measurements and thyroid histopathology have been evaluated. 
Data are available in male and female rats following 14 and 90 days of 
e ~ ~ o s u r e , ' ~ " ~  female mice following 90 days of e ~ ~ o s u r e , ' ~ " ~  rat dams on 
9,19,20 gestation day 20, post natal day 5, postnatal day 10, and male and 
female pups on post natal days 5, 10, and 22. 9~19,20 
A 90-day subchronic bioassay determined that the thyroid was the only target 
organ in male and female rats exposed to perchlorate in drinking water (0, 
0.01, 0.05, 0.2, 1.0, and 10 mglkg-day) for 90 days. The no observable 
adverse effect level (NOAEL) based on thyroid changes was 1 mglkg-day 
but hormone changes, decreased T4 and increased TSH, were still seen at the 
lowest doses.I6 
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Genotoxicity assays showed that perchlorate has no toxic effects on genes or 
chromosomes in cells.2' Perchlorate is not a teratogen as no birth defects 
were found at doses as high as 100 mg/kg-day in the rabbit22 or as high as 30 
mgtkg-day in the rat.23 Immunotoxicity studies were motivated by case 
reports of aplastic anemia and leukopenia in humans when perchlorate was 
used in high doses as an anti-thyroid drug. Studies using female mice did not 
demonstrate any adverse effects to the immune system. Evaluation of 
thyroid responses identified no alterations in T3 and TSH, while T4 was 
decreased after exposure to 1.0, 3.0 or 30 mglkg-day. Thyroid changes 
detected histologically were not seen in all animals until the 30.0 mgtkg-day 
dose.17 
Developmental neurotoxicity studies exposed pregnant rats to perchlorate in 
drinking water (0, 0.1, 1 .O, 3.0 and 10 mglkg-day) during pregnancy through 
day 10 of lactation.24 No pup behavioral effects were seen except marginal 
motor activity results at one time point. An additional motor activity study 
with the same doses found no statistically significant effects in motor 
However, a Bayesian statistical analysis conducted using data 
from the two different motor activity studies combined resulted in a NOAEL 
of 1.0 mg/kg-day. Hormone changes, decreased T, and increased TSH, were 
again seen at lower doses. Brain histology and morphometry changes seen in 
this developmental study were not dose dependent and resulted in larger 
measured values. Iodine deficiency should produce decreases in brain 
structure size.24 Another study was planned as a result of the brain data. 
The additional major study performed was referred to as the "Effects" Study. 
The objectives were to refine understanding of the effects of perchlorate in 
the thyroid gland and to evaluate brain development at critical time 
The brain analysis attempted to provide better brain morphometry 
data than the developmental study described above. The study was designed 
to provide critical information for the perchlorate risk assessment, so data 
were collected at one fetal and three postnatal (during lactation) time points. 
The fetal time point also rovided rat teratogenic results to compare with the 
2y23 
rabbit teratogenic study. Hormone changes, decreased T, and increased 
TSH, were again seen at lower doses. However, the brain morphometry was 
equivocal because the changes seen were once again not dose dependent or 
resulted in larger measured values. Subsequent evaluation of the 
methodology used in this and the previous developmental neurotoxicity 
raised questions about preparation of the brain tissue for microscopic 
analysis, including orientation of the slices through the brain. The 
interpretation of the brain morphometry data has been debated as a result. 
PERCHLORATE TOXICITY AND RISK ASSESSMENT 173 
A two-generation reproductive toxicity study was used to evaluate fertility in 
adult rats and viabilityltoxicity in their offspring.27 Reproductive parameters 
were tested over two generations of drinking water exposure to perchlorate. 
The NOAEL for reproduction effects is greater than the highest dose tested, 
30 mglkg-day. Thyroid histology changes were seen starting at 3 mglkg-day. 
There were three rare benign thyroid tumors identified by a Pathology 
Working Group in two first generation (F1) pups at the 30 mglkg-day dose. 
However, the occurrence of this tumor was not statistically significant as it 
was also found in control animals. 
Perchlorate Use as a Drug in Humans 
Potassium or sodium perchlorate was used clinically to treat Graves' disease 
(hyperthyroidism, thyrotoxicosis) in the 1950s and 1960s. Anti-thyroid 
drugs act by either blocking iodide uptake into the thyroid or by blocking 
thyroid hormone (Tj and T4) synthesis in the thyroid. The recommended 
dose was 800 to 1000 mglday, although doses varied from 200 to 2000 
mglday. Perchlorate was given as either a single large dose or as a daily dose 
for weeks, months or even years in some cases. The use of perchlorate as a 
drug became limited in the mid-1960s due to reports of agranulocytosis and 
fatal aplastic anemia.28 
More recently, amiodarone has been used to treat patients with ischemic 
heart disease or with ventricular tachycardia; this drug has a potential side 
effect of hyperthyroidism. A dose of 1000 mglday potassium perchlorate has 
been used to treat amiodarone-induced hyperthyroidism. Potassium 
perchlorate may also be used if a patient is sensitive to standard antithyroid 
drugs. The perchlorate discharge test was used clinically to diagnose thyroid 
function. In this test, a single large dose of perchlorate caused iodide 
discharge from the thyroid if there was a problem with the organification 
process, which is the incorporation of iodide into thyroid hormones.28 
Human Health Effects 
Epidemiological studies have examined the associations of thyroid effects 
and environmental exposure to perchlorate in public drinking water at levels 
ranging from 4 to 120 ppb (4 to 120 pg/L). A number of the studies have 
small sample sizes and cannot detect differences in frequency of outcomes 
between exposure groups. Adjustments for potentially confounding factors 
were limited. Nearly all the studies were ecologic (epidemiological studies 
without individual exposure characterization), including those in newborns 
and children, the groups potentially most vulnerable to the effects of 
perchlorate exposure. Ecologic studies can provide supporting evidence of a 
possible association but cannot provide definitive evidence regarding cause. 
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Perchlorate exposure of individual subjects is difficult to measure and was 
not assessed directly in any of the published studies conducted outside the 
occupational setting. 
Perchlorate was found in Las Vegas and the surrounding county at levels 
averaging 14 ppb (pg/L). Congenital hypothyroidism data from the 1996 and 
1997 neonatal screening program were examined; no increase in congenital 
hypothyroidism was observed.29 From April 1998 to June 1999, the monthly 
mean T4 levels of neonates from Las Vegas (an area with perchlorate- 
contaminated drinking water at 9 to 15 ppb (pg/L) for eight months and non- 
detectable (< 4 ppb) contamination for 7 months) were compared with those 
of neonates from Reno (an area with no detectable perchlorate in its drinking 
water). There were no differences in neonatal T4 levels between the cities.30 
An analysis of newborn TSH levels from Las Vegas and Reno was 
conducted for babies born December 1998 through October 1999 at normal 
birth weight and having their blood sampled within the first month of life. 
The mean blood TSH levels were not different between the cities.31 Another 
Las Vegas vs. Reno comparison examined thyroid disease prevalence rates 
among Medicaid-eligible residents. Thyroid disease included simple goiter, 
nodular goiter, thyrotoxicosis, congenital hypothyroidism, acquired 
hypothyroidism, thyroid cancer or other thyroid diseases. Again there were 
no differences between the cities.32 One study examined a possible relation 
between perchlorate exposure and adverse neurodevelopmental outcomes in 
children and did not see any association between perchlorate and attention 
deficit hyperactivity disorder (ADHD) or autism.33 
Data on thyroid hormone and TSH production in newborns and congenital 
hypothyroidism were also examined by Brechner et a1.,34 ~chwartz ,~ '  Kelsh 
et ~ a m m ~ ~  and Buffler et ~ 1 . ~ ~  Although hormone changes were 
reported in areas of California and Arizona, the prevalence of congenital 
hypothyroidism was not associated with perchlorate exposure. Morgan and 
 assa ad^^^ addressed the incidence of cancer after dual exposure to 
perchlorate and trichloroethylene. Incidence of cancers was not observed 
more often than expected in children. 
A number of studies collected clinical data from adult human volunteers in a 
controlled setting after exposure to known amounts of perchlorate in drinking 
water ranging from 0.007 to 12 mglkg per day. These clinical studies 
measured inhibition of iodide uptake into the thyroid glands as well as TSH 
and thyroid hormones. Serum TSH levels did not increase and thyroid 
hormones did not decrease in any group. Brabant et ~ 1 . ~ '  conducted a 4 week 
study with subjects given 12 mglkg per day. Thyroid iodide and TSH 
decreased and thyroid hormones did not change. Although only preliminary 
data are available, a study in which volunteers were given 0.007 and 0.04 
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mglkg-day perchlorate for 6 months resulted in no effects on thyroid 
f~nct ion.~ '  
Two 14-day studies were conducted in which 10 mglday was provided in 
water to 10 male subjects and 3 mglday was provided in drinking water to 8 
male In both studies, each subject served as their own control 
by having measurements taken before and after perchlorate consumption. 
123 
Iodide was measured in the thyroid to obtain inhibition data, and iodide 
and perchlorate were determined in blood and urine. Perchlorate, at both 3 
and 10 mglday, caused inhibition of iodide uptake into the thyroid (38% and 
lo%, respectively). There were no changes seen in TSH or thyroid hormone 
levels in the blood. The extrapolated no observable effect level (NOEL) for 
iodide inhibition was 2 mglday based on these two exposures. 
Another 14-day study employed 10 subjects (5 male15 female) for each dose 
(0.5, 0.1, 0.02 and 0.007 mglkg-day) who also served as their own contr01.'~ 
123 The parameters measured were iodide uptake in the thyroid for inhibition 
data and iodide and perchlorate in blood and urine for kinetic data. There 
were no changes seen in TSH or thyroid hormone levels in the blood. The 
NOEL for iodide inhibition, measured as decreased uptake of iodideli3 in the 
thyroid, was 0.007 mglkg-day. Data from these studies were used to develop 
the human PBPK model for perchlorate. 
Employees were examined at an ammonium perchlorate production facility 
in Nevada and their findings compared to those of a large unexposed control 
population from the same industrial complex.3 The average working-lifetime 
cumulative dose in the higher exposure group was estimated to be 38 mglkg. 
Based on both cumulative and single-shift perchlorate exposures, there were 
no adverse effects on thyroid, kidney, liver or bone marrow function. A 
cross-sectional health study of two similar worker populations, a group of 
ammonium perchlorate workers divided into three exposure groups and a 
comparison group of other workers from the same industrial complex, was 
conducted at a perchlorate manufacturing plant in ~ t a h . ~ ~  More than 40% of 
the exposed employees had been working with perchlorate for more than five 
years. There were no effects on blood and clinical chemical parameters at 
any level of exposure up to 34 mg per day. 
A second occupational study of perchlorate exposure was conducted at the 
same site in Utah. Serum perchlorate levels averaged 838 ppb (yg1L) during 
exposure with a calculated daily dose of 0.167mglkg-day perchlorate. 
Although iodide inhibition averaged 38%, TSH did not change and thyroid 
hormones actually increased slightly but significantly.4 
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School-age children were examined in three cities in northern Chile where 
levels of naturally occurring perchlorate in the water supply were 
undetectable, 5-7 and 100-120 ppb (ugh.,). In the school children (mean age 
7.3 years), 127 of whom had lifelong residence in their respective cities, 
mean TSH, T4, and T3, were similar among the three cities. Incidence of 
goiter in the lifelong residents was similar in all three cities; although the 
residents in Taltal self-reported a higher incidence of family history of 
thyroid disease. No changes were found in congenital hypothyroidism, and 
clinical differences between children from the three different cities. This was 
the only ecologic study with measures of perchlorate made directly from 
drinking-water samples taken from homes in the area where subjects lived.45 
Free T4 was significantly increased in children living in Taltal and Chanaral, 
compared with Antofagasta (control city), a change in the opposite direction 
than expected. A variable introduction of iodized salt started in 1982 and 
may have affected these observations. Crump et aL4' also studied newborns 
screened for hypothyroidism by a heel-stick blood sample between February 
1996 and January 1999 in the same three Chilean cities. TSH levels were 
significantly lower in Taltal than in the other two cities, a trend opposite to 
that hypothesized. The authors concluded that the differences did not appear 
clinically significant. 
A second epidemiological study was conducted in the same Chilean cities. 
Water was analyzed from the tap in the home of every subject. Perchlorate, 
at daily levels as high as 114 ppb (pg/L) throughout pregnancy, did not affect 
maternal thyroid status early in gestation, alter fetal thyroid status at birth, or 
reduce breast milk iodine  concentration^.^^ 
Summary of Toxicity 
The competitive inhibition of iodide uptake is the only direct perchlorate 
effect on the thyroid, leading to a reversible chemical-induced iodine 
deficiency. Alteration of hormones (T4, T3, TSH) would be the first observed 
biological effect of perchlorate exposure. Following a prolonged increase in 
TSH, thyroid hyperplasia progressing to thyroid tumors would be expected to 
occur in rodents. However, the relevance of these tumors to humans has 
been questioned, since this progression has not been observed in humans.47 
In contrast, human data show that decreased T4 levels, both in pregnant 
women and in neonates, can lead to neuro-developmental deficit; although 
this has not been confirmed in animals following perchlorate exposure. 
Therefore, of the two pathways to altered structure and function proposed by 
a mode-of-action analysis for perchlorate, decreased T4 leading to potential 
neurodevelopmental effects is more relevant to an assessment of human 
health. 
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This conclusion is also supported by National Research ~ o u n c i l . ~ ~  The NRC, 
on behalf of the DoD, EPA, DOE and NASA, formed a committee in 2003 to 
conduct an assessment of key scientific issues associated with the health 
effects of perchlorate. This committee in its report48 judged that the 
development of thyroid tumors as an ultimate result of perchlorate exposure 
is an unlikely outcome in human based on two considerations: (1) rats are 
sensitive to the development of thyroid tumors because their thyroid function 
is easily disrupted; (2) humans are much less susceptible than rats to 
disruption of thyroid function and therefore are not likely to develop thyroid 
tumors as a result of perchlorate exposure. Therefore, NRC committee 
concluded that the most reasonable pathway of events after changes in 
thyroid hormone and TSH secretion would be thyroid hypertrophy or 
hyperplasia, possibly leading to hypothyroidism.48 The hypothyroidism 
would lead to two potential outcomes (as summarized in Figure 1): (1) 
metabolic sequelae, such as decreased metabolic rate and slowing of the 
function of many organ systems, occurring at any age, and (2) abnormal 
growth and development in fetuses and children. 
Following oral exposure in drinking water, serum perchlorate levels increase 
and provide a measure of the perchlorate internal dose. The mechanism of 
action also identifies that perchlorate has a threshold for effects and that the 
degree of effects are dependent on the dosage. Severe or sustained iodine 
deficiency can lead to hypothyroidism. However, a temporary disruption of 
iodine leads to temporary effects that are reversed with the proper levels of 
iodine ingestion in the diet. In rodents, sustained exposure to a chemical that 
causes hypothyroidism can lead to thyroid tumors, a mechanism that has not 
been demonstrated in humans. There remains disagreement on what is the 
first adverse or critical effect after perchlorate exposure. 
PERCHLORATE RISK ASSESSMENT 
Identification of critical effect 
One risk assessment goal is to determine what exposure might be considered 
"safe." "Safe" or subthreshold doses are defined by a number of health 
agencies worldwide. Although many of the underlying assumptions, 
judgments of critical effect, and choices of uncertainty factors are similar 
among health agencies in estimating these subthreshold doses, this section 
will follow U.S. EPA's Reference Dose (RfD)  method^.^^'^^,^' 
The first step in defining an RfD is to identify the critical effect(s). U.S. 
EPA 52 and Haber et ~ 1 . ~ ~  define critical effect(s) as the first adverse 
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effect(s), or its known precursor, that occurs as dose rate or exposure level 
increases. In the determination of critical effect, it is crucial that distinctions 
be drawn between adverse effects and adaptive effects. An adaptive effect 
enhances an organism's performance as a whole and/or its ability to 
withstand a challenge; an adverse effect is a biochemical change, functional 
impairment, or pathological lesion that impairs performance and reduces the 
ability of an organism to respond to additional Available 
animal studies as described above clearly suggest that the thyroid is the 
primary target organ for perchlorate. Thus, distinguishing adaptive from 
adverse effects in the thyroid and determining the most appropriate adverse 
effect on which to base an RfD was the first step in the perchlorate risk 
assessment. 
Inhibition of iodine uptake in thyroid, the key event in the ultimate disruption 
of thyroid function, can be considered as a marker of the biologically 
effective dose for perchlorate. However, inhibition of iodine uptake, itself, 
cannot be considered an adverse effect because in humans we do not yet 
know what levels of iodine uptake inhibition would decrease T4 levels. 
Alteration of hormone levels, including decrease of serum T4 and T3 with a 
corresponding increase of TSH, is considered to be the early biological effect 
of exposure to perchlorate. The human body has a large reserve capacity of 
circulating thyroid hormone; serum levels of T4 and T3 are highly variable. 
No clear-cut information is available on how much decrement of circulating 
serum T4 can be tolerated without resulting in permanent alteration of thyroid 
function. However, subclinical hypothyroidism is generally considered to be 
present when circulating TSH levels are elevated by 2-fold, with, or without 
decreased levels of ~ 4 . ~ ~  
Based on a mode-of-action analysis, it is clear that altered hormone levels are 
an early biological effect of perchlorate exposure. If allowed to persist, 
increased TSH levels, at least in rodents, will eventually lead to thyroid 
hyperplasia and possible thyroid tumors. Even if this pathway is not relevant 
to humans, persistent decreases in T4 levels increase the potential for 
neurodevelopmental deficits in children. In this case, decreased T4 can be 
considered to be a precursor to an adverse effect, rather than an adverse 
effect in itself, however, because changes in T4 are routinely compensated by 
normal, and well understood, homeostatic processes. Therefore, decreases in 
serum T4 in the pregnant population should be considered to be the critical 
effect most relevant to human health. The NRC committee48 also reached the 
same conclusion and considered that the first adverse effect in the model-of- 
action model is hypothyroidism. 
CHAPTER 8 
Choice of appropriate species and study 
US EPA's policy when developing RfDs in many of its program, regional 
offices, and Office of Research and Development (ORD) has been to use 
human data first and foremost in the determination of critical effect and 
choice of uncertainty factors. The preference for use of human data is found 
in many EPA publications, risk positions, risk methods documents, and 
In general, using human data as the basis for developing an RfD 
will reduce the uncertainty inherent in extrapolating from rat data. 
The available data on the effects of perchlorate in experimental animals 
consistently points to thyroid disturbance as the sentinel effect. This 
disturbance may lead to subsequent thyroid and neurological damage. This 
information in experimental animals is consistent with the available, but 
more limited, human data. However, these data also demonstrate that rats 
may respond to perchlorate exposures in a very different manner than 
humans.55 The reason that such comparisons are not definitive is that the 
human data do not include information on pregnant individuals. 
Although the rat data set includes the sensitive subgroup (the pregnant 
animal and its fetus), whereas the human studies only include measurements 
of TSH and T4 in adults, infants and children (and not pregnant individuals), 
rats are known to be more sensitive than humans to thyroid hormone 
replacement therapy, needing 10 times more T4 than humans to achieve a 
euthyroid ~ o n d i t i o n . ~ ~  Because the overall uncertainty in determining an 
RfD is greater from the rat data, when compared with the human data, the 
human data are the appropriate choice for determining an RfD. The NRC~* 
also concluded that the human data provided a more reliable point of 
departure for the risk assessment than the animal data. 
Of the available human studies, one clinical study1' and one epidemiology 
study45 were considered to yield sufficient information to determine an RfD. 
Greer study was a well-conducted study underwent a rigorous quality 
assurance audit and conforms to the "Common Rule" the Federal Agency 
Guidelines on the ethical conduct of human studies.57 This study observed 
no statistically significant effects in serum T4, T3, or TSH even at the highest 
dose tested, and defines a NOAEL of 0.5 mgtkg-day for the healthy adult 
human population for short-term exposure. The Crump et study found 
no evidence that perchlorate in drinking water at concentrations as high as 
120 ug/L suppressed thyroid function in newborns or school-aged children. 
Crump et also studied newborns screened for hypothyroidism by a heel- 
stick blood sample between February 1996 and January 1999 in the same 
three Chilean cities. TSH levels were significantly lower in Taltal (high 
exposure city) than in the other two cities, a trend opposite to that 
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hypothesized. The authors concluded that the differences did not appear 
clinically significant. 
One issue to address in the use of Crump et ~ 1 . ~ ~  study as a basis of an RfD is 
the apparent iodine excess when compared with other populations, such as 
the U.S. A 1 to 2.5-fold excess in urinary iodine seen in the Chilean school 
children may serve to protect this population from perchlorate exposure. 
However, a second study with pregnant women in the same cities of Chile 
with lower iodine supplementation had the same results as the Crump et ~ 1 . ~ ~  
Point-of-departure analysis 
Following accepted risk assessment approaches, a point-of-departure analysis 
establishes the threshold dose that serves as the starting point for developing 
the RfD. Traditionally, the point of departure for an RfD has been the No 
Observed Adverse Effect Level (NOAEL), which is the highest experimental 
dose that is without adverse effect. More recently, risk assessors have 
attempted to incorporate more of the data about the dose response curve by 
using benchmark dose (BMD) modeling. BMD modeling uses quantitative 
dose response models to estimate the dose that results in a specified change 
(such as 10%) in the critical effect, or its precursor. 
No human study involved exposures high enough to cause a decrease in T4; 
therefore, all of the human studies can be said to have identified 
"freestanding NOAELs" for the critical effect. The highest NOAEL 
identified in the body of human studies is approximately 0.5 mglkg-day. 
This dose was achieved in workers exposed for an average of 8 and 
in healthy adults exposed for 14 days in a clinical study.'' The lowest 
NOAEL observed in a human is an estimated NOAEL of 0.006 
mglkg-day (actual exposure is an average of 0.1 12 mglL) measured in 
school-age children who had been exposed in utero and for their entire 
lifetime (about 7 years). Because, these children were exposed in utero and 
as neonates, the NOAEL from this study is a freestanding NOAEL in a 
sensitive population. Therefore, a NOAEL of 0.5 mglkg-day could be 
considered as a point-of-departure for the general human population, while 
0.006 mglkg-day could be a point-of-departure for a sensitive human 
population. 
However, use of a freestanding NOAEL does incorporate some uncertainty 
into the risk assessment because the true threshold for the critical effect has 
not been identified. In other words, the true threshold, or true NOAEL, is 
likely to be higher than the NOAEL used as the point-of-departure. 
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Therefore, using this freestanding NOAEL would result in a more 
conservative risk value. 
The Greer et a1.I0 study adequately characterizes the dose-response curve for 
inhibition of iodine uptake in humans. This effect of perchlorate is a key 
event of the mode of action because it is the essential step in the cascade 
leading to adverse effects. Without inhibition of iodine uptake, there will be 
no alteration of T4 or TSH or subsequent adverse effects on neurological 
development and thyroid hyperplasia. Therefore, a point-of-departure based 
on inhibition of iodine uptake is a health-protective surrogate that can be 
used to replace a freestanding NOAEL for decreased T4. The lowest dose 
evaluated by Greer et a1.,I0 0.007 mglkg-day, did not cause a statistically 
significant inhibition of iodine uptake. Based on a regression analysis taking 
into account the variability of the experimental population, the authors 
predicted that the dose that would result in 0% inhibition of iodine uptake is 
0.0064 mglkg-day; the 95% upper confidence limit on iodine uptake 
inhibition at this dose is 8.3%. Greer et a1.I0 concluded that an iodine uptake 
inhibition less than 10% would not be biologically significant. This 
threshold of 0.006 mglkg-day, as well as the lowest dose evaluated by Greer 
et al.,1° 0.007 mglkg-day, are reasonable point-of-departures for estimating 
an R ~ D . ~ ~ , ~ ~  
Currently, insufficient data exist to adequately define the level of iodine 
uptake inhibition in humans that can be tolerated for a lifetime without 
altering serum T4 and TSH levels. Greer et a1.I0 demonstrated that for 14-day 
exposure, inhibition of iodine uptake up to about 70%, has no effect on 
serum T4 or TSH. Occupational s t ~ d i e s ~ , ~ ~  demonstrated that workers 
exposed to perchlorate for several years demonstrated no altered T4 or TSH 
serum levels. When the serum hormone levels from these studies are plotted 
against serum perchlorate AUC predicted by the human PBPK model, it can 
be seen that chronic exposure in workers had no effect on serum T4 or TSH 
at serum AUC values that resulted in approximately 50% I uptake 
i n h i b i t i ~ n . ~ ~  Thus, it might be reasonable to conclude that an appropriate 
benchmark response would be the perchlorate dose that resulted in a 50% 
inhibition of iodine uptake. Nonetheless, benchmark response levels of 10% 
inhibition of iodine uptake was modeled in order to be public health 
protective and take into account the uncertainties involved in extrapolating 
data from healthy adults to potential sensitive populations such as iodine 
deficient people, pregnant women, and neonates. 
Based on BMD modeling results from Strawson et ~ 1 . , ~ *  the perchlorate dose 
that caused a 10% inhibition of iodine uptake is 0.01 mglkg-day (BMD10); 
the its 95% lower limit (BMDL10) estimate ranges from 0.004 mglkg-day 
(Hill model) to 0.008 mglkg-day (Power model). These results are consistent 
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with the conclusions of Greer et al., which indicated that the no effect level 
for iodine inhibition ranges from 0.006 (predicted) to 0.007 (measured) 
mglkg-day. 
Therefore, for the purpose of developing a perchlorate RfD, four different 
points-of-departure could have been used: a freestanding NOAEL of 0.5 
mglkg-day for the general, healthy population, a freestanding NOAEL of 
0.006 mgtkg-day for a sensitive subpopulation; the lowest dose evaluated by 
Greer et al.,1° 0.007 mglkg-day; and a threshold for iodine uptake inhibition 
of 0.006 mglkg-day used as a health-protective surrogate for the freestanding 
NOAELs. 
Choice of uncertainty factors 
The judgment of the appropriate uncertainty factor is based on a review of 
the information supporting the choice of critical effect, and issues associated 
with extrapolation from experimental animals to humans and to sensitive 
humans. The noncancer risk assessment by U.S. EPA" incorporates five 
different uncertainty factors to address issues of variability and uncertainty. 
Interspecies and intraspecies factors are used to address the uncertainty 
between experimental animals and humans, and the variability within 
different human populations. Three other factors (Subchronic, LOAEL, 
Database) are used to address lack of information. Typically, the maximum 
total uncertainty factor that U.S. EPA will apply is 3000. If all five areas of 
uncertaintylvariability are present warranting a total UF of 10,000, then U.S. 
EPA" generally concludes that the uncertainty is too great to develop an 
RfD. 
I .  Interspecies Variability (UFA) 
This factor accounts for the differences that occur between animals and 
humans and is also thought to be composed of subfactors for toxicokinetics 
(how the body distributes and metabolizes the chemical) and toxicodynamics 
(how the body responds to the chemical). If no information is available on 
the quantitative differences between animals and humans, then a default 
value of 10 is used. If information is available on one of the two 
subcomponents, then this information (chemical specific adjustment factor, 
CSAF) is used along with a default value of 3 for the remaining s u b f a c t ~ r . ~ ~  
If data are available to adequately describe variability in both subfactors, 
then actual data may be used to replace default values. If an RfD is based on 
human data, then a value of 1 is appropriate for this factor. 
The body of data in experimental animals demonstrates that the rodent 
response to perchlorate is dramatically different than the human response. In 
184 CHAPTER 8 
rats, doses that cause only about 10% iodine uptake inhibition cause variable, 
but statistically significant changes in hormone levels. While in humans, 
doses that cause 70% iodine uptake inhibition have no effect on hormone 
levels. Basing the RfD on animal data will introduce greater uncertainty to 
the RfD than use of human data. Therefore, human data is the best basis for 
the RfD. If the proposed points-of-departure which are obtained from human 
studies are used, a factor of 1 is appropriate for this area of uncertainty. 
Otherwise, an uncertainty factor as high as 10 should be applied when animal 
data are used as the point-of-departure. 
2. Intraspecies Variability (UFH) 
This factor accounts for the natural differences that occur between human 
subpopulations and for the fact that some individuals may be more sensitive 
than the average population. Similar to the interspecies uncertainty factor, 
this factor is also composed of two subfactors - one to account for 
toxicokinetic differences and one to account for toxicodynamic differences. 
If no information is available on human variability, then a default value of 10 
is used. However, if adequate information is available on one or both of the 
two subcomponents, then this information is used along with a default value 
of 3 for the remaining s~bfactor.~ '  In addition, if an RfD is based on human 
data gathered in the known sensitive subpopulation, a value of less than 10, 
perhaps even 1, may be chosen for this factor. 
The judgment of appropriate intraspecies uncertainty factor depends in part 
on the choice of study as the basis of the RfD. For perchlorate exposure, the 
available data are insufficient to develop a CSAF for human variability at 
this time. When the RfD is based on the freestanding NOAEL of 0.5 mglkg- 
day identified in the healthy adult population,'0 a full factor of 10 is 
appropriate to use because this NOAEL does not account for the fact that a 
NOAEL in sensitive subgroups (i.e., children or pregnant mothers with their 
fetuses) could be lower. In contrast, a lower factor is appropriate for the 
freestanding NOAEL of 0.006 mglkg-day identified in children45 because 
this study covers at least one of the sensitive subpopulation, children. In the 
Crump et study, the presence of perchlorate in the water has been a long- 
term problem. The mothers of the children evaluated were exposed before 
pregnancy, so that if perchlorate were affecting thyroid function in these 
women, they would already be hypothyroid at the start of pregnancy. The 
children themselves were exposed as fetuses in the uteri, as neonates, and 
throughout their lifetimes. Therefore several of the life stages that are 
considered sensitive have been studied in the Crump et a1.I0 study. 
Therefore, the observation of a freestanding NOAEL in this study gives 
greater confidence that fetuses, neonates, and children will be protected by an 
RfD based on this point-of-departure. However, an uncertainty factor of 3, 
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rather than 1, is appropriate to use with this point-of-departure because there 
are no data to suggest how the other sensitive subpopulation, e.g., pregnant 
women, may respond. 
When iodine uptake inhibition is used as a point-of-departure, the use of an 
uncertainty factor should be based on data addressing the variability of iodine 
uptake inhibition in human population. Mattie et have used 
physiologically based pharmacokinetic models for both rats and humans to 
predict perchlorate doses that will result in a 5% iodine uptake inhibition in 
different life stages. In rats, the predicted doses that result in a 5% inhibition 
are 0.03 mglkg-day, 0.05 mglkg-day, and 0.13 mglkg-day for male rats, 
pregnant rats, and lactating rats, respectively. In humans, the predicted doses 
that result in a 5% inhibition are 0.01 mglkg-day, 0.025 mglkg-day, and 
0.061 mglkg-day for healthy adult males and females, pregnant women, and 
lactating women, respectively. This analysis suggests that pregnant women 
are not more sensitive to iodine. uptake inhibition than healthy adults. In 
addition, it confirms that the physiology of pregnancy serves to conserve 
iodine uptake, making pregnant women less sensitive to iodine uptake 
inhibition than non-pregnant adults. Thus, Strawson et a/." concluded that 
no extra uncertainty factor is necessary when iodine uptake inhibition data 
from the human study is used as a point-of-departure to derive an RfD. 
However, the NRC" recommended use of a full factor of 10 to protect the 
most sensitive population, the fetuses of pregnant women who might have 
hypothyroidism or iodide deficiency. The NRC committee viewed its 
recommendation as conservative and health-protective because the point of 
departure is based on a non-adverse effect that precedes the adverse effect in 
the continuum of possible effects of perchlorate exposure (see Figure 1). 
Therefore, the appropriate choice for intraspecies uncertainty factor is either 
10-fold with the use of the Greer et al.1° NOAEL for T4 decrease in adults, 3- 
fold with the use of the Crump et NOAEL for T4 decrease in children, or 
10 fold with the use of the Greer et a1." threshold for iodine uptake 
inhibition. 
3. Subchronic to Chronic Extrapolation (UFs) 
Because the RfD protects for a lifetime exposure, this factor is applied when 
the database lacks information on the health effects of the chemical following 
a chronic exposure. If the database contains no information on chronic 
exposure, a default value of 10 is often applied, unless other data suggest a 
lack of progression with exposure duration. If the database contains 
adequate chronic bioassays, then a value of 1 is generally appropriate. If 
there are data addressing only one of the two issues, then a default of 3 may 
be applied. Thus, the need for a duration UF for perchlorate depends on 
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whether more sensitive effects are expected after increasing duration of 
exposure, or whether longer durations of exposure increase the severity or 
decrease the point of departure for perchlorate's critical effect. 
While there are no studies that cover a full lifetime in either animals or 
humans for the thyroid effects of concern, there are studies that evaluate 
longer exposures in humans and studies that demonstrate no increase in the 
severity of effects with increasing duration in animals. In Gibbs et al. (1998) 
study, workers' tenure ranged from 1 to 27 years, with an average of 8 years. 
In Lamm et study, 40% of the workers had a tenure greater than 5 years. 
In Crump et study, children age 6-8 years who had been exposed their 
entire lives were evaluated. In all three of these studies parameters 
investigated include general physical exam, tests of kidney and liver 
function, and blood counts, as well as tests of thyroid function. No effects on 
any of these parameters were observed in the exposed populations in these 
studies. When compared to the results of the 14-day clinical studies in 
humans, 10,42,43 these longer-term studies show that increasing duration of 
exposure in humans does not increase the incidence or severity of thyroid 
effects, nor does it induce effects in other target organs that were not 
identified by the short-term studies. Although only preliminary data are 
available, a study in which volunteers were given 0.007 and 0.04 mglkg-day 
perchlorate for 6 months resulted in no effects on thyroid function and 
further supports these  conclusion^.^^ 
The available animal studies also support the conclusion that increasing 
exposure duration does not result in an increase in incidence or severity of 
thyroid effects nor does it reveal non-thyroid effects that are not detected by 
shorter-term studies. Several studies have evaluated perchlorate after either 
14 days15,16.17,60 or 90 days.16,17,60 These studies have evaluated systemic and 
immunotoxic effects in addition to thyroid effects. None of these studies 
observed any non-thyroid effects after either 14 or 90 days of exposure, 
suggesting that increased exposure duration will not result in systemic effects 
that occur at lower doses than thyroid effects. Although the thyroid response 
is variable, particularly the hormone changes, these studies also show that 
animals exposed for 90 days do not show a clear pattern of more severe 
hormone changes nor an accelerated progression of thyroid pathology to 
hyperplasia compared with animals exposed for 14 days. 
Strawson et also reviewed duration affect on inhibition of iodine uptake 
by perchlorate in animals and humans. Rats up-regulate iodine uptake very 
quickly during 14-day treatment and that inhibition actually decreases with 
time.9 In contrast, humans do not up-regulate iodine uptake within the same 
time period.10 However, these data do show that iodine uptake inhibition 
does not increase with increasing duration in either rats or humans. 
PERCHLORATE TOXICITY AND RISK ASSESSMENT 187 
Animals or humans exposed to perchlorate for a prolong duration may 
develop other effects which didn't occur in short-tem studies, e.g., thyroid 
adenomas in F1 generation male rats of a two-generation However, 
it is known that thyroid tumors in rats are ultimately caused by constant 
stimulation of the thyroid by TSH. It is also known that perchlorate at 30 
mglkg-day caused dramatic increases in TSH in these animals. Thus, it is not 
necessarily surprising that tumors were evoked at such a high level of 
exposure. Nevertheless, the development of thyroid tumors in rats is not a 
duration effect per se, but rather a threshold phenomenon. If perchlorate 
doses stay below a level that induce increased TSH levels, then the 
production of thyroid tumors is not possible according to the proposed mode 
of action (Figure 2).21,47 Increased duration of perchlorate at doses that are 
below this threshold will not increase the risk of thyroid tumor formation. In 
addition, while the development of thyroid tumors in rats can be considered 
to be qualitatively relevant to humans, there are questions about whether 
humans do, in fact, develop thyroid tumors by the same mechanism. 
'1 Exposure , 
I Susceptibility I 
Figure 2. Mode of action model for perchlorate toxicity proposed by U.S. EPA (2003b). 
Perchlorate interferes with the sodium (NA+)-iodide (I-) symporter (NIS) present in various 
tissues, particularly thyroid. The model shows the exposure-dose response continuum 
considered in the context of biomarkers (classified as measures of exposure, effect, and 
susceptibility) and level of organization at which toxicity is observed (adapted directly from 
U.S. EPA.~' 
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Based these considerations, a value of 1 appears to be appropriate to address 
this area of uncertainty. Both the human and animal studies demonstrate that 
increasing exposure duration does not result in the appearance of non-thyroid 
effects at doses lower than the thyroid hormone effects. Thyroid effects in 
humans and rodents do not increase in incidence or severity with increasing 
exposure duration. Inhibition of iodine uptake does not increase in humans 
or rats with increasing exposure duration. The NRC~' agreed that this 
uncertainty factor should be 1. 
4. LOAEL to NOAEL Extrapolation (UFd 
Because the RfD is considered to be a subthreshold value that protects 
against any adverse health effects, this factor is applied when the database 
lacks information to identify a NOAEL. If the database does not identify a 
NOAEL, then a default of 10 is used for this factor. If a NOAEL is used, a 
value of 1 is appropriate. Often, if the database does not identify a NOAEL, 
but the adverse effects observed are of minimal severity, then a default of 3 
will be considered appropriate for use of a "minimal LOAEL". 
Both the Greer et al.1° and the Crump et ~ 1 . ~ '  studies identified freestanding 
NOAELs for the critical effect of decreased T4. When either of these 
NOAELs is used as the point-of-departure for the development of an RfD, an 
uncertainty factor of 1 for this area would be appropriate. A point-of- 
departure at the threshold for iodine uptake inhibition (the lowest dose in 
Greer et a1.)I0 is, likewise, not considered to be a LOAEL, because inhibition 
of iodine uptake is a key event in the mode of action rather than an adverse 
effect.48 In addition, this point of departure represents a dose at which no 
inhibition of iodine uptake occurs, so that adverse effects cannot occur 
following exposure to this dose. This conclusion is confirmed by the body of 
human data, which demonstrate that no effect on serum hormone levels has 
been observed at doses equal to or higher than this point of departure. 
Therefore, this point-of-departure should be considered as a NOAEL 
surrogate, rather than a LOAEL surrogate, and the appropriate value for this 
factor is 1. The NRC" agreed that this uncertainty factor should be 1. 
5. Database (UFO) 
Based on US EPA's risk assessment methodology, the database for deriving 
a high confidence RfD includes at a minimum two chronic bioassays by the 
appropriate route of exposure in different species, one two-generation 
reproductive toxicity study, and two developmental toxicity studies in 
different species. The minimal database required for deriving an RfD is a 
single subchronic bioassay, that includes a full histopathology examination. 
The database factor is used to account for the fact that a potential health 
effect may not be identified if the database is missing a particular type of 
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study. This factor may also be used if the existing data indicate the potential 
for a heath effect that is not fully characterized by the standard bioassays, for 
example neurotoxicity or immunotoxicity. If the database is complete, a 
value of 1 is appropriate. If only the minimal database is available, then a 
default of 10 is used. A value of 3 may be used if the database is missing one 
or two key studies. 
The database for perchlorate includes an large number of experimental 
animal studies, including chronic (but older) studies that show tumors at high 
doses,61 numerous shorter-term bioassays that unequivocally demonstrate 
that thyroid disturbance occurs at lower doses than other systemic, 
immunotoxic, genotoxic, or other effects, developmental toxicity studies in 
two species, a 2 generation reproduction study that also monitored systemic 
effects in young rats, a developmental neurotoxicity study, a specialized 
developmental toxicity study to monitor hormone changes in early life and 
during late pregnancy and lactation, and a specialized neurobehavioral study 
to confirm earlier findings. The database also includes human clinical, 
experimental, epidemiology, and occupational studies. 
All of this information demonstrates that the thyroid is the most sensitive 
organ system. In humans, the threshold for iodine uptake inhibition is well 
characterized and additional studies are not likely to provide different 
information that would change the risk assessment. In humans, the 
perchlorate dose that causes a decrease in T4, the critical effect, is not well 
characterized since no human population has been exposed to a dose high 
enough to alter hormone levels. However, if these studies could be 
performed, their effect would likely be to raise the NOAEL. The mode of 
action analysis suggests a potential for adverse effects as a result of serum T4 
levels that are consistently depressed by at least 60%. The doses that cause 
this degree of T4 decrease are not well characterized in either humans or 
animals. However, by selecting a point-of-departure that is below the 
threshold for any T4 change, subsequent effects will not develop. Therefore, 
the overall perchlorate database is complete, and any new studies that are 
conducted to fine tune our knowledge of the perchlorate mode of action will 
not identify lower points-of-departure than can be estimated from the 
existing database. Based on these considerations, the appropriate value for 
this factor is 1. 
In summary, when human data are used as the point-of-departure, the only 
area of uncertainty for a perchlorate RfD that needs to be addressed by the 
use of uncertainty factors is human variability and the difference in response 
between pregnant women and the groups for which data are available. A 
factor of 1 is appropriate to address all other areas of uncertainty. The NRC 
committee48 recommended the use of a composite uncertainty factor of 10 to 
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protect the fetuses of pregnant women who might have hypothyroidism or 
iodide deficiency. 
Developing the RfD 
As shown by extensive animal studies, the critical effect of perchlorate is T4 
serum decrease. Pregnant rats are demonstrated to be the most sensitive 
subgroup, likely followed by the young rat. Several human studies exist that 
monitored for this critical effect. These human studies do not include 
pregnant women, but they do include children. In addition, comparative data 
between the experimental animal and human indicate that humans are not 
more sensitive than the experimental animal species tested to T4 serum 
decrease by perchlorate; in fact based on toxicodynamics parameters they are 
much less ~ensitive.'~ The most relevant data for developing the RfD for 
perchlorate exposures comes from human epidemiology and clinical studies, 
supplemented with available and extensive information on experimental 
animals. All these data support the use of the human data for development of 
an R ~ D . ~ ~  
The NRC Committee report,48 "Health Implications of Perchlorate 
Ingestion," recommended using the data from the Greer study for deriving a 
reference dose (RfD) for perchlorate. Animal and clinical studies conducted 
since 1997 were all designed based on the mechanism of action for 
perchlorate, inhibition of iodide uptake. This mechanism of action has been 
a point of agreement between toxicologists and risk assessors throughout the 
process to develop the perchlorate risk assessment. There remains 
disagreement on what is the first adverse or critical effect after perchlorate 
exposure. The NRC committee avoided all disagreements by using the 
NOEL for inhibition of iodide uptake from the Greer study as the point of 
departure when they recommended an RfD for perchlorate. According to the 
NRC report,48 there is an added level of conservatism or protection, since 
inhibition of iodide uptake is the first step in a multi-step process prior to 
causing an adverse effect. The NRC committee48 recommended use of a 
composite uncertainty factor of 10 to protect the fetuses of pregnant women 
who might have hypothyroidism or iodide deficiency. The US Environmental 
Protection Agency (USEPA) agreed and developed their RfD based on the 
NRC recommendation (0.007 mg/kg-day point-of-departure x UF of 10). 
The USEPA listed the oral reference dose (RfD) for perchlorate as 0.0007 
mg/kg-day (24.5 ppb drinking water equivalent) in their Integrated Risk 
Information System (IRIS). 
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SUMMARY AND IMPLICATIONS 
There are currently many unanswered questions surrounding the prevalence 
of perchlorate in the environment, the possible exposures and effects, and the 
risk management strategies available to manage perchlorate contamination. 
Further information must be obtained in each of these areas in order to 
develop successful and appropriate strategies for handing perchlorate 
contamination now and in the future. Because of the uncertainty involved in 
evaluating toxicological data, the states and federal agencies using this 
information may use and interpret it somewhat differently to promulgate 
different standards and advisory levels. It is important to note that the status 
of the knowledge of perchlorate exposure and risks continues to evolve and it 
will be essential to periodically re-evaluate what is known about this 
chemical. However, the reference dose recommended by National Research 
Council and adopted by the U.S. Environmental Protection Agency will 
protect the health of even the most sensitive groups of people over a lifetime 
of exposure. 
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